ARE · Q2 2025 Earnings

Management's posture this quarter is meaningfully more defensive than the company's typical megacampus growth narrative. The shift sits on five axes:

From leasing momentum to leasing quality. The prior framing emphasized venture funding tailwinds and biotech expansion driving demand. This quarter, Hallie characterized life-science venture funding as merely "steady, with nearly $22 billion deployed in the first half of the year" while noting "seed stage financings took the back burner to more de-risk technologies closer or already in human studies." Leasing is now being attributed to high-quality tenant flight and M&A-driven consolidation, not market-wide demand acceleration. That is a quieter, more defensive demand signal.

From occupancy stability to explicit near-term pressure. Mark stated: "Occupancy at the end of the quarter was at 90.8%, which was down 90 basis points from the prior quarter" and "we expect continued pressure on same property results in the second half of 2025 driven by the recent decline in occupancy." Pairing the current print with a -3.7% to -1.7% FY same-property NOI guide is management telegraphing that the trough is not yet in.

From development pipeline advancement to cost discipline. Mark: "For construction spending, we are evaluating some of our 2027 redevelopment projects for alternative lower-cost investment opportunities and hope to have more to report over the coming quarters." This is a clear pivot from aggressive capex deployment toward optionality and re-prioritization — a signal that elevated rates and tenant hesitancy are reshaping how ARE thinks about its 2027 pipeline.

From "macro will resolve" to "macro persists." Joel's commentary that "Fears of spending cuts and changes at HHS may be substantially overblown" is paired with "Key details remain unclear, and we know there is negotiations going on" on drug pricing. The hedging language ("may be," "limited concern so far") sits awkwardly against the optimism — management is acknowledging that FDA delays, NIH budget gridlock, MFN pricing, and tariffs are ongoing rather than transitory drags on tenant decision velocity.

From onshoring tailwind to consolidation narrative. On the big-pharma build-to-suit, Joel was explicit: "No, that didn't have anything to do with the onshoring issues that are currently underway with respect to administration policies. It was more an effort by a notable big pharma to bring together its poor R&D hub on the West Coast." Management is deliberately not riding the onshoring policy narrative — the win is positioned as brand equity, not macro tailwind. Joel's "Trust is the lifeblood of the Alexandria one-of-a-kind brand" reframes the lease as differentiation-led rather than demand-led.